HuidaGene Therapeutics
Shanghai · Founded 2018
About HuidaGene Therapeutics
HuidaGene utilizes its proprietary CRISPR-based, AI-driven HG-PRECISE platform to develop potentially curative gene therapies. The Company is advancing clinical programs, including trials of HG004 (granted ODD & RPDD by FDA) for RPE65-associated retinal disease, HG202 RNA-editing therapy for nAMD, HG204 RNA-editing therapy (granted ODD & RPDD by FDA and ODD by EMA) for MECP2 duplication syndrome, and HG302 DNA-editing therapy (granted ODD & RPDD by FDA) for DMD. The preclinical programs include HG303 DNA-editing for ALS and CRISPR RNA-editing therapy for Alzheimer’s.
Company Facts
- Founded: 2018
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $14.2M
- Funding stage: Late Stage Venture
- Last round: Series C (May 2022)
- Website: http://www.huidagene.com/
- Phone: 15221536625
Industries & Categories
Biopharma, Biotechnology, Genetics, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/huidagene-therapeutics-83076 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.